PH30943A - N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents. - Google Patents
N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents.Info
- Publication number
- PH30943A PH30943A PH48245A PH48245A PH30943A PH 30943 A PH30943 A PH 30943A PH 48245 A PH48245 A PH 48245A PH 48245 A PH48245 A PH 48245A PH 30943 A PH30943 A PH 30943A
- Authority
- PH
- Philippines
- Prior art keywords
- thioesters
- acid esters
- acyl
- sulfonamides
- carbamic acid
- Prior art date
Links
- 150000007970 thio esters Chemical class 0.000 title 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000000260 hypercholesteremic effect Effects 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6251593A | 1993-05-14 | 1993-05-14 | |
| US08/223,932 US5491172A (en) | 1993-05-14 | 1994-04-13 | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH30943A true PH30943A (en) | 1997-12-23 |
Family
ID=26742358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH48245A PH30943A (en) | 1993-05-14 | 1994-05-11 | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5633287A (no) |
| EP (1) | EP0698010B1 (no) |
| JP (1) | JP3704149B2 (no) |
| AT (1) | ATE178891T1 (no) |
| AU (1) | AU681152B2 (no) |
| CA (1) | CA2158268C (no) |
| CZ (1) | CZ290683B6 (no) |
| DE (1) | DE69417885T2 (no) |
| DK (1) | DK0698010T3 (no) |
| ES (1) | ES2133163T3 (no) |
| FI (1) | FI955438A0 (no) |
| GR (1) | GR3030356T3 (no) |
| HU (1) | HU223044B1 (no) |
| IL (1) | IL109431A (no) |
| NO (1) | NO305861B1 (no) |
| NZ (1) | NZ266689A (no) |
| PH (1) | PH30943A (no) |
| RU (1) | RU2137756C1 (no) |
| SG (1) | SG47056A1 (no) |
| SK (1) | SK282790B6 (no) |
| WO (1) | WO1994026702A1 (no) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE9800037A (et) * | 1995-08-04 | 1998-08-17 | Warner-Lambert Company | Sulfaamhappe derivaatide, atsüülsulfoonamiidide või sulfonüülkarbamaatide kasutamine lipoproteiini tasemeid vähendava ravimi valmistamiseks |
| ATE348607T1 (de) * | 1995-11-02 | 2007-01-15 | Warner Lambert Co | Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration |
| US6093744A (en) * | 1997-04-21 | 2000-07-25 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| CA2382676A1 (en) * | 1999-11-05 | 2001-05-17 | Warner-Lambert Company | Prevention of plaque rupture by acat inhibitors |
| DE10016544A1 (de) * | 2000-04-03 | 2001-10-11 | Bayer Ag | C2-phenylsubstituierte Ketoenole |
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| JP2004532799A (ja) | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| JP2004511453A (ja) | 2000-10-11 | 2004-04-15 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロールの制御及び関連する使用のためのケトン化合物及び組成物 |
| US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| US20040072903A1 (en) * | 2001-05-08 | 2004-04-15 | Auerbach Bruce Jeffrey | Carboxyalkylether-acat inhibitors combinations |
| EP1281399A3 (en) * | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
| US20030236213A1 (en) * | 2002-04-10 | 2003-12-25 | Jean-Louis Dasseux | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
| HUE036646T2 (hu) * | 2003-01-23 | 2018-07-30 | Esperion Therapeutics Inc | Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra |
| NZ544803A (en) * | 2003-08-29 | 2009-11-27 | Kowa Co | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| BR0318685A (pt) * | 2003-12-24 | 2006-12-19 | Esperion Therapeutics Inc | compostos de cetona e composições para controle de colesterol e usos relacionados |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| NZ555325A (en) * | 2004-10-27 | 2009-07-31 | Daiichi Sankyo Co Ltd | Benzene compound having 2 or more substituents |
| BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
| WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
| ATE492541T1 (de) | 2006-05-30 | 2011-01-15 | Astrazeneca Ab | Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase |
| MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
| BRPI0821274A2 (pt) | 2007-12-20 | 2017-06-13 | Astrazeneca Ab | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica |
| JP5291979B2 (ja) | 2008-04-24 | 2013-09-18 | 株式会社フジクラ | 圧力センサ及びその製造方法と、該圧力センサを備えた電子部品 |
| EP2341924A4 (en) | 2008-10-02 | 2013-01-23 | David Gladstone Inst | METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
| US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
| EP2443096A1 (en) | 2009-06-19 | 2012-04-25 | AstraZeneca AB | Pyrazine carboxamides as inhibitors of dgat1 |
| US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| ES2886953T3 (es) * | 2016-01-15 | 2021-12-21 | Bayer Cropscience Ag | Procedimiento para la preparación de 2-(4-cloro-2,6-dimetilfenil)etanol |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166633A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| AU2020295503A1 (en) | 2019-06-21 | 2022-01-27 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3377375A (en) * | 1963-02-07 | 1968-04-09 | Monsanto Co | N-aralkylsulfonyl carbamates |
| US3622626A (en) * | 1968-12-18 | 1971-11-23 | Minnesota Mining & Mfg | N-acylated perfluoroalkanesulfonamides |
| US3560563A (en) * | 1969-06-03 | 1971-02-02 | American Home Prod | 2-(p-alkylphenyl)-n-sulfonylalkanoyl-amides |
| US3833608A (en) * | 1970-11-23 | 1974-09-03 | Merck Sharp & Dohme | Indole-3-methanesulfonamides |
| DE4110795A1 (de) * | 1991-04-04 | 1992-10-08 | Bayer Ag | Sulfonylaminocarbonyltriazolinone mit ueber sauerstoff gebundenen substituenten |
| US5186736A (en) * | 1988-08-02 | 1993-02-16 | Hoechst Aktiengesellschaft | Heterocyclic N-acylsulfonamides and their use as herbicides or growth regulators |
| DE3916663A1 (de) * | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| NZ233752A (en) * | 1989-05-24 | 1993-05-26 | Merck Frosst Canada Inc | Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof |
| IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
| EP0409332A3 (en) * | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
| DE3935277A1 (de) * | 1989-10-24 | 1991-05-02 | Hoechst Ag | Sulfonierte heterocyclische carboxamide, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als herbizide oder wachstumsregulatoren |
| EP0517812A4 (en) * | 1990-02-13 | 1995-10-18 | Merck & Co Inc | Angiotensin ii antagonists incorporating a substituted benzyl element |
| WO1991015209A1 (en) * | 1990-03-30 | 1991-10-17 | Merck & Co., Inc. | Substituted pyrimidines, pyrimidinones and pyridopyrimidines |
| EP0461040A1 (fr) * | 1990-06-08 | 1991-12-11 | Roussel Uclaf | Dérivés de l'imidazole, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant |
| DE4023040A1 (de) * | 1990-07-20 | 1992-01-23 | Bayer Ag | Herbizide auf basis von sulfonylierten (thio)carbamidsaeureestern, neue sulfonylierte carbamidsaeureester und verfahren zu deren herstellung |
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| DE69106386T2 (de) * | 1990-10-30 | 1995-05-04 | Warner Lambert Co | Oxysulfonylcarbamate. |
| US5245068A (en) * | 1990-10-30 | 1993-09-14 | Warner-Lambert Company | Oxysulfonyl carbamates |
| US5198466A (en) * | 1990-11-09 | 1993-03-30 | Warner-Lambert Company | Oxysulfonyl urea acat inhibitors |
| DE4105551A1 (de) * | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| GB9105297D0 (en) * | 1991-03-13 | 1991-04-24 | Schering Agrochemicals Ltd | Herbicides |
| US5190968A (en) * | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
| US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| WO1993010086A1 (de) * | 1991-11-13 | 1993-05-27 | MTA Központi Kémiai Kutató Intézete | Verfahren zur herstellung von n-(arylsulfonyl)-carbamid-säure-derivaten und den in diesem verfahren verwendbaren intermedieren |
| GB2263635A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
| GB2263639A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| GB2263637A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists |
| GB2263638A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists |
| US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
-
1994
- 1994-04-26 IL IL10943194A patent/IL109431A/en not_active IP Right Cessation
- 1994-05-11 AU AU68311/94A patent/AU681152B2/en not_active Ceased
- 1994-05-11 PH PH48245A patent/PH30943A/en unknown
- 1994-05-11 AT AT94916734T patent/ATE178891T1/de not_active IP Right Cessation
- 1994-05-11 HU HU9502811A patent/HU223044B1/hu not_active IP Right Cessation
- 1994-05-11 CA CA002158268A patent/CA2158268C/en not_active Expired - Fee Related
- 1994-05-11 NZ NZ266689A patent/NZ266689A/en not_active IP Right Cessation
- 1994-05-11 EP EP94916734A patent/EP0698010B1/en not_active Expired - Lifetime
- 1994-05-11 JP JP52567494A patent/JP3704149B2/ja not_active Expired - Fee Related
- 1994-05-11 SK SK1396-95A patent/SK282790B6/sk unknown
- 1994-05-11 DE DE69417885T patent/DE69417885T2/de not_active Expired - Lifetime
- 1994-05-11 WO PCT/US1994/005233 patent/WO1994026702A1/en active IP Right Grant
- 1994-05-11 RU RU95122768A patent/RU2137756C1/ru not_active IP Right Cessation
- 1994-05-11 DK DK94916734T patent/DK0698010T3/da active
- 1994-05-11 ES ES94916734T patent/ES2133163T3/es not_active Expired - Lifetime
- 1994-05-11 CZ CZ19952966A patent/CZ290683B6/cs not_active IP Right Cessation
- 1994-05-11 SG SG1996004778A patent/SG47056A1/en unknown
-
1995
- 1995-10-23 US US08/546,967 patent/US5633287A/en not_active Expired - Lifetime
- 1995-11-10 FI FI955438A patent/FI955438A0/fi unknown
- 1995-11-13 NO NO954564A patent/NO305861B1/no unknown
-
1999
- 1999-05-27 GR GR990401448T patent/GR3030356T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6831194A (en) | 1994-12-12 |
| JP3704149B2 (ja) | 2005-10-05 |
| NO954564D0 (no) | 1995-11-13 |
| ATE178891T1 (de) | 1999-04-15 |
| WO1994026702A1 (en) | 1994-11-24 |
| EP0698010A1 (en) | 1996-02-28 |
| DE69417885T2 (de) | 1999-09-30 |
| IL109431A (en) | 2001-01-11 |
| FI955438A (fi) | 1995-11-10 |
| CZ296695A3 (en) | 1996-09-11 |
| JPH08510256A (ja) | 1996-10-29 |
| EP0698010B1 (en) | 1999-04-14 |
| IL109431A0 (en) | 1994-07-31 |
| HUT72653A (en) | 1996-05-28 |
| CA2158268C (en) | 2006-11-07 |
| NZ266689A (en) | 1997-11-24 |
| SG47056A1 (en) | 1998-03-20 |
| FI955438A0 (fi) | 1995-11-10 |
| SK282790B6 (sk) | 2002-12-03 |
| GR3030356T3 (en) | 1999-09-30 |
| DK0698010T3 (da) | 1999-10-25 |
| RU2137756C1 (ru) | 1999-09-20 |
| NO305861B1 (no) | 1999-08-09 |
| SK139695A3 (en) | 1996-11-06 |
| AU681152B2 (en) | 1997-08-21 |
| CA2158268A1 (en) | 1994-11-24 |
| NO954564L (no) | 1996-01-11 |
| DE69417885D1 (de) | 1999-05-20 |
| US5633287A (en) | 1997-05-27 |
| CZ290683B6 (cs) | 2002-09-11 |
| HU9502811D0 (en) | 1995-11-28 |
| HU223044B1 (hu) | 2004-03-01 |
| ES2133163T3 (es) | 1999-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3030356T3 (en) | N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents | |
| DK0659174T3 (da) | Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler | |
| AU586248B2 (en) | (Meth)-acrylic acid esters and their use | |
| AU5827086A (en) | (Meth) -Acrylic acid esters and the use thereof | |
| EA199800109A1 (ru) | Производные азетидинона для лечения атеросклероза | |
| CA2151149A1 (en) | Novel ring opening monomers | |
| DE69425804T2 (de) | Phosphonsäurediesterderivate | |
| DK0635497T3 (da) | Benzospiroalkenderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger, der indeholder disse | |
| EP0807627A3 (en) | Anilide compounds as ACAT inhibitors | |
| DE69005974D1 (de) | Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten. | |
| DK0696585T3 (da) | Nyt bisoxadiazolidinderivat | |
| ZA966617B (en) | New methods of using n-acyl sulfamic acid ester (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters). | |
| ES8404151A1 (es) | Procedimiento para la preparacion de nuevos derivados de acidos (di)-tiofosforicos y fosfonicos. | |
| PT90814A (pt) | Processo de preparacao de derivados da fenotiazina | |
| SE8303913L (sv) | Heterocykliska foreningar | |
| AU2586384A (en) | Pesticidal alkyl,aryl(thio)phosphous esters and amides | |
| ES2001701A6 (es) | Un metodo para preparar compuesto de benzoilurea | |
| MX9709275A (es) | Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas. | |
| ES481741A1 (es) | Procedimiento para la obtencion de o-(amino alquil) oximas diaromaticas. |